Skip to main content

Table 1 Basic characteristics of the included studies

From: Efficacy and safety of tranexamic acid in posterior lumbar interbody fusion: a meta-analysis of randomized controlled trials

Study

Intervention measures

N (Male/Female)

Age (years)

Weight (kg)

TXA

CG

TXA

CG

TXA

CG

Elwatidy et al. [14]

30 mg/kg + 1 mg/(kg h)

A + B

32 (21/11)

32 (18/14)

51.56 + 19.08

49.75 + 21.04

72.48 ± 13.81

69.63 ± 17.29

Wong et al. [15]

10 mg/kg + 1 mg/(kg h)

A + B

73 (21/52)

74 (26/48)

56.8 ± 16.2

50.0 ± 16.2

72.9 ± 17.2

73.9 ± 16.1

Liang et al. [16]

2000 mg

C

30 (15/15)

30 (14/16)

51.13 ± 10.72

53.50 ± 10.26

26.2 ± 4.1 (BMI)

25.3 ± 5.2 (BMI)

Shi et al. [17]

30 mg/kg + 2 mg/(kg h)

A + B

50 (25/25)

46 (22/24)

53.76 ± 12.06

55.87 ± 13.14

63.10 ± 10.82

62.13 ± 9.98

Nagabhushan et al. [3]

10 mg/kg + 1 mg/(kg h)

A + B

25 (9/16)

25 (11/14)

49.60 ± 9.79

51.72 ± 9.71

58.84 ± 3.31

60.96 ± 7.35

Kim et al. [18]

10 mg/kg + 2 mg/(kg h)

A + B

24 (12/12)

24 (15/9)

61.0 ± 9.0

65.2 ± 7.0

25.9 ± 3.2 (BMI)

25.1 ± 3.2 (BMI)

Wang et al. [19]

10 mg/kg + 1 mg/(kg h)

A + B

39 (25/18)

41 (18/19)

41.2 ± 10.3

42.5 ± 9.5

63.2 ± 18.3

64.3 ± 19.1

Mu et al. [20]

15 mg/kg

A

45 (27/18)

42 (23/19)

54.20 ± 7.37

52.57 ± 6.73

24.83 ± 1.95 (BMI)

23.93 ± 1.35 (BMI)

Ou et al. [21]

15 mg/kg + 1 g

A + C

59 (30/29)

59 (31/28)

64.2 ± 4.6

64.0 ± 5.1

22.64 ± 3.29 (BMI)

22.57 ± 3.20 (BMI)

Sun et al. [22]

15 mg/kg

A

26 (15/11)

37 (22/15)

57.12 ± 11.55

51.51 ± 13.57

24.86 ± 4.72 (BMI)

24.44 ± 3.57 (BMI)

Xu et al. [23]

1 g

C

30 (13/17)

30 (14/16)

49.6 ± 12.8

50.6 ± 16.2

25.3 ± 3.0 (BMI)

25.7 ± 3.0 (BMI)

Zhang et al. [24]

1 g + 1 g

A + C

151 (57/94)

138 (47/91)

54.73 ± 9.93

57.04 ± 10.20

25.82 ± 3.28

25.20 ± 3.54

Li et al. [25]

2 g + 1 g

A + C

212 (74/138)

227 (84/143)

55.4 ± 10.61

55.26 ± 10.44

25.73 ± 3.31 (BMI)

25.71 ± 3.63 (BMI)

Yan et al. [26]

20 mg/kg + 10 mg/(kg h)

A + B

40 (16/24)

40 (22/18)

53 ± 7

52 ± 8

25.4 ± 3.1 (BMI)

24.4 ± 3.4 (BMI)

  1. A Intravenous use; B Intraoperative maintenance; C Local use; BMI Body mass index; CG Control group; TXA Tranexamic acid group